Mark Cuban tries to shake up biosimilar pricing with a version of J&J’s Stelara
In its latest bid to shake up the prescription drug market, the Mark Cuban Cost Plus Drug Company…
New FDA priority review vouchers go to Lilly, Novo, Vertex
WASHINGTON — The Food and Drug Administration on Thursday announced the second batch of companies being granted a “Commissioner’s…
Launch prices for new drugs ‘significantly’ exceed inflation, analysis says
Amid intensifying angst over prescription drug prices, a new analysis found that the median net price for 154…
ctDNA blood test could change how cancer is treated
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
Lyra Health launches ‘clinical-grade’ mental health chatbot
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics.…
Startup tech helps Parkinson’s disease patients track symptoms
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics.…
Digital health M&A picks up, driven by AI and private equity
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics.…
Coverage of Sarepta Duchenne drug may be halted by N.Y. state Medicaid
In a setback for Sarepta Therapeutics, a New York panel has voted unanimously to recommend the state Medicaid…
Parents flock to Tylenol alternatives amid Trump autism claims
When President Trump warned that pregnant women and children should avoid taking Tylenol, the wellness industry was ready…
Tylenol’s 70-year history: From kids’ drug to political controversy
Megan Molteni reports on discoveries from the frontiers of genomic medicine, neuroscience, and reproductive tech. She joined STAT…
Acadia Pharmaceuticals drug for rare genetic condition fails late-stage study
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
FDA cracks down on prescription drug ads but lacks staff
WASHINGTON – In an unprecedented move, federal regulators published about 100 warning letters sent to pharmaceutical companies and health…